On Wednesday, Shares of Host Hotels and Resorts Inc (NYSE:HST), subtract -0.13% and closed at $15.41 in the last trading session. The last trading range of the stock ranges between $15.28 and $15.66. The company’s Market capitalization is $11.40 Billion with the total Outstanding Shares of 712.48 million. Host Hotels & Resorts, Inc. is a publicly owned real estate investment trust (REIT). The firm mainly engages in the ownership and operation of hotel properties. It invests in the real estate markets of United States. It also invests in Canada, Mexico, Chile, the United Kingdom, Italy, Spain, and Poland. The firm mainly invests in luxury and upper upscale hotels.
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), jumped 3.82% and closed at $13.87 in the last trading session. The last trading range of the stock ranges between $13.41 and $13.98. The company’s Market capitalization is $2.63 Billion with the total Outstanding Shares of 192.71 million.ARIAD Pharmaceuticals, Inc. (ARIA) recently declared that its partner Otsuka Pharmaceutical Co., Ltd. (Otsuka) has received approval from the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) for Iclusig® (ponatinib) for the treatment of chronic myeloid leukemia (CML) resistant or intolerant to preceding drug treatment and relapsed or treatment resistant Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
“Our partnershipwith Otsuka has resulted in recently’s approval of Iclusig in Japan, providing an important new treatment for patients with refractory CML and Ph+ ALL,” stated Paris Panayiotopoulos, president and chief executive officer of ARIAD. “Japan represents a large market opportunity for Iclusig and its first approval in Asia. We are committed to expanding patient access and to continuing our successful partnership with Otsuka as evidenced by recent marketing applications for Iclusig presented in Korea and Taiwan.”
This approval triggers a $10 million milestone payment to ARIAD from Otsuka under the parties’ partnershipagreement entered in December 2014.
”Treatment failure affects a substantial proportion of CML patients treated with tyrosine kinase inhibitors because of resistance or intolerance. For these patients living with CML in Japan, we are grateful to have Iclusig as a new approved treatment option,” said Arinobu Tojo, M.D., Ph.D, deputy director, Research Hospital, The Institute of Medical Science at the University of Tokyo.
Hess Corp. (NYSE:HES), gained 2.35% and closed at $53.48 in the last trading session. The last trading range of the stock ranges between $52.82 and $53.87. During the 52-week trading session the minimum price at which share price traded, registered at $32.40 and reached to max level of $64.08. Hess Corporation (HES) declared recently the consideration to be paid in the formerly declared cash tender offer (the “Maximum Tender Offer”) to purchase up to about $324.0 million (the “Aggregate Maximum Repurchase Amount”) of the following series of notes issued by Hess (the “Notes”):
7.875% Notes due 2029;
7.300% Notes due 2031; and
7.125% Notes due 2033.
The Maximum Tender Offer was made following the terms and conditions set forth in the offer to purchase dated September 19, 2016 (the “Offer to Purchase”).